Connor Clark & Lunn Investment Management Ltd. boosted its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) by 42.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,893 shares of the specialty pharmaceutical company’s stock after purchasing an additional 6,845 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in KalVista Pharmaceuticals were worth $337,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in the stock. GSA Capital Partners LLP bought a new stake in shares of KalVista Pharmaceuticals during the 4th quarter valued at about $152,000. Virtus ETF Advisers LLC boosted its holdings in shares of KalVista Pharmaceuticals by 66.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 12,482 shares of the specialty pharmaceutical company’s stock worth $165,000 after acquiring an additional 4,988 shares during the period. JPMorgan Chase & Co. boosted its stake in KalVista Pharmaceuticals by 24.9% during the first quarter. JPMorgan Chase & Co. now owns 13,424 shares of the specialty pharmaceutical company’s stock valued at $198,000 after buying an additional 2,677 shares during the period. Corton Capital Inc. bought a new stake in KalVista Pharmaceuticals during the fourth quarter valued at $212,000. Finally, New York State Common Retirement Fund raised its position in KalVista Pharmaceuticals by 32.7% during the first quarter. New York State Common Retirement Fund now owns 16,810 shares of the specialty pharmaceutical company’s stock valued at $248,000 after purchasing an additional 4,147 shares in the last quarter.
KalVista Pharmaceuticals Trading Down 4.1 %
Shares of KALV opened at $16.14 on Monday. The firm has a market cap of $396.58 million, a PE ratio of -4.80 and a beta of 1.71. KalVista Pharmaceuticals, Inc. has a 1-year low of $8.00 and a 1-year high of $21.76. The firm has a fifty day simple moving average of $13.16 and a two-hundred day simple moving average of $12.92.
In related news, CEO Thomas Andrew Crockett sold 1,797 shares of the stock in a transaction dated Wednesday, August 17th. The shares were sold at an average price of $14.96, for a total value of $26,883.12. Following the sale, the chief executive officer now directly owns 112,178 shares of the company’s stock, valued at approximately $1,678,182.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 8.30% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have recently commented on KALV. Needham & Company LLC decreased their price objective on KalVista Pharmaceuticals from $42.00 to $38.00 and set a “buy” rating on the stock in a report on Friday, July 8th. SVB Leerink cut their price objective on KalVista Pharmaceuticals from $51.00 to $45.00 and set an “outperform” rating on the stock in a research report on Friday, July 8th.
KalVista Pharmaceuticals Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
- Get a free copy of the StockNews.com research report on KalVista Pharmaceuticals (KALV)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.